SignalXSignalX

IBRX ImmunityBio, Inc.

FY2025 10-K
Filed: Feb 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR
ImmunityBio, Inc. Overview

ImmunityBio, Inc. (IBRX) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business: Development and commercialization of biologic drugs, with focus on regulatory approvals and post-marketing requirements
  • • New emphasis on commercialization efforts for approved product ANKTIVA and building sales, marketing, and distribution capabilities
+3 more insights

Management Discussion & Analysis

  • • Revenue started from ANKTIVA sales since May 2024; no dollar amounts or YoY change disclosed
  • • Operating expenses expected to increase substantially due to commercialization and R&D expansion; no margin % figures provided
+3 more insights

Risk Factors

  • • Regulatory risk from potential NCCN guideline decision on BCG-unresponsive NMIBC papillary-only disease expansion expected Q1/Q2 2026
  • • Geopolitical exposure via dependency on 33 countries with ANKTIVA approval including US, UK, EU, Saudi Arabia, and MENA launches
+3 more insights

Financial Summary
XBRL

Revenue

$113M

Net Income

-$351M

Operating Margin

-226.0%

Net Margin

-310.2%

ROE

70.2%

Total Assets

$502M

EPS (Diluted)

$-0.38

Operating Cash Flow

-$305M

Source: XBRL data from ImmunityBio, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.

Get deeper insights on ImmunityBio, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available